Italia markets close in 50 minutes

FTSE MIB
34.564,36
-260,65(-0,75%)
Dow Jones
39.866,93
+60,16(+0,15%)
Nasdaq
16.792,64
-2,24(-0,01%)
Nikkei 225
38.946,93
-122,75(-0,31%)
Petrolio
79,20
-0,60(-0,75%)
Bitcoin EUR
65.177,38
+3.603,09(+5,85%)

NVCR Jul 2024 30.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

1,0000

-0,2500

(-20,00%)

In data: 03:55PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in